Results 1 to 10 of about 290,432 (308)

Tocilizumab for Steroid Pulse-Refractory Cytokine Release Syndrome in Chemotherapy With Durvalumab Plus Tremelimumab for NSCLC: A Case Report

JTO Clinical and Research Reports
Immune checkpoint inhibitors have dramatically improved the prognosis of NSCLC. However, various immune-related adverse events (irAEs) have been reported. Cytokine release syndrome (CRS) is an irAE that is occasionally severe and life-threatening. CRS is
Ken Yamamoto, MD, Katsuya Hirano, MD, Temiko Shimada, MD, PhD, Akito Hata, MD   +3 more
doaj   +1 more source

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis

Iranian Journal of Allergy, Asthma and Immunology, 2016
Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2, have been regarded as important immune system regulatory molecules. The aberrant expression of the molecules has been related to several autoimmune disorders.
Mohammad Reza Javan, Saeed Aslani, Mohammad Reza Zamani, Javad Rostamnejad, Milad Asadi, Mahdi Farhoodi, Mohammad Hossein Nicknam   +6 more
doaj  

Programmed Necrosis: A Prominent Mechanism of Cell Death following Neonatal Brain Injury

Neurology Research International, 2012
Despite the introduction of therapeutic hypothermia, neonatal hypoxic ischemic (HI) brain injury remains a common cause of developmental disability. Development of rational adjuvant therapies to hypothermia requires understanding of the pathways of cell ...
Raul Chavez-Valdez, Lee J. Martin, Frances J. Northington   +2 more
doaj   +1 more source

Toxicity Associated with Pembrolizumab Monotherapy in Patients with Gastrointestinal Cancers: A Systematic Review of Clinical Trials

Biomedicines
Background/Objectives: Pembrolizumab, an immune checkpoint inhibitor targeting programmed death 1 (PD-1), is a widely employed therapy for various gastrointestinal (GI) cancers.
Nikolas Naleid, Amit Mahipal, Sakti Chakrabarti   +2 more
doaj   +1 more source

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

npj Breast Cancer
Additional therapies are needed to improve outcomes in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative breast cancer.
Fatima Cardoso, Kim M. Hirshfield, Kimberly A. Kraynyak, Konstantinos Tryfonidis, Aditya Bardia   +4 more
doaj   +1 more source

Incidental improvement of programmed cell death-1 receptor inhibitor-induced vitiligo after initiation of dupilumab therapy for refractory pruritus. [PDF]

JAAD Case Rep, 2023
Robinson W, McLellan BN.
europepmc   +1 more source

Twenty-One Flavors of Type 1 Innate Lymphoid Cells with PD-1 (Programmed Cell Death-1 Receptor) Sprinkles. [PDF]

Discov Immunol, 2023
Smith KJ, Sciumè G, Amarnath S.
europepmc   +1 more source

Programmed cell death-1 receptor-mediated regulation of Tbet⁺NK1.1^- innate lymphoid cells within the tumor microenvironment. [PDF]

Proc Natl Acad Sci U S A, 2023
Lim JX, Lai CY, Mallett GE, McDonald D, Hulme G, Laba S, Shapanis A, Payne M, Patterson W, Alexander M, Coxhead J, Filby A, Plummer R, Lovat PE, Sciume G, Healy E, Amarnath S.   +16 more
europepmc   +1 more source

D-1 Gene Polymorphism in Salivary Gland Tumors

Journal of Dental School, 2019
Objectives This study aimed to assess PD-1gene polymorphism in salivary gland tumors in patients referred to Khalili Hospital in Shiraz. Methods This case-control study evaluated 48 patients with salivary gland tumors and 100 age- and sex-matched ...
Jannan Ghapanchi, Behnam Samavatian, Hamid Ghaderi, Bijan Khademi, Elham Mahmoudi Maymand, Elaheh Ainy   +5 more
doaj   +1 more source

Real-world effectiveness of first-line immunotherapy with or without chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer

Frontiers in Immunology
This real-world retrospective study evaluated the effectiveness of first-line immunotherapy with or without chemotherapy compared with chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC).
Lihua Li, Juan Du, Jing Yang, Limin Chai, Jingxu Nie, Xinfeng Cai, Linxiu He, Junting Jia, Rong Ma, Yimeng Guo   +9 more
doaj   +1 more source